The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications ... suggesting a potential impact on the neural mechanisms associated with addiction[1][2]. This aligns with findings ...

Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut that plays a crucial role in regulating metabolism, particularly in glucose homeostasis and appetite control. It is secreted by ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long ... showed multiple steps and did not follow a standard nucleation-propagation mechanism. A wide range of ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.